At Eladdis, we specialise in supporting public sector organisations to deliver complex transformation programmes through a unique blend of clinical expertise, commercial insight, and strategic delivery capability. Our approach ensures that procurement and service redesign are not only technically sound but also clinically informed, patient-centred, and outcome-driven.

Drawing on recent experience supporting national-level procurement initiatives in diabetes care, this article explores how effective clinical engagement can unlock better outcomes, smarter investment, and greater equity across the system.

In the evolving landscape of healthcare procurement, the importance of clinical engagement cannot be overstated. When done well, it ensures that products and services are not only cost-effective but also clinically appropriate, safe, and aligned with the needs of both patients and professionals.

Recent work in the diabetes technology space—particularly around continuous glucose monitoring (CGM), insulin pumps, and hybrid closed-loop systems—has demonstrated the transformative impact of engaging clinical leaders early and meaningfully in the procurement process.

Bridging Clinical Insight and Commercial Strategy

Drawing on experience from national-level procurement initiatives, it is clear that the most effective outcomes are achieved when clinical and commercial perspectives are integrated from the outset. By engaging clinicians with deep expertise in diabetes care, procurement teams were able to:

• Ensure products were fit for purpose, meeting the diverse needs of people living with Type 1 diabetes
• Support equitable access, helping to reduce health inequalities through consistent national availability
• Improve patient safety and outcomes, by selecting technologies that support self-management and reduce acute episodes
• Deliver clinical and financial value, aligning procurement with long-term system benefits

Key Features of a Strategic Framework Approach

While the specifics of the framework remain confidential, the approach taken offers valuable lessons for future initiatives:

• Comprehensive product coverage, including CGM devices, insulin pumps (tethered and patch), and closed-loop components
• Phased implementation, aligned with national clinical guidance and digital readiness
• Supplier standards, including sustainability, social value, and innovation readiness
• Centralised ordering, simplifying access for healthcare providers
• Substantial investment, reflecting the scale and importance of the technology in modern diabetes care

The Benefits of Effective Engagement

The outcomes of this approach speak for themselves:

• Improved access to life-changing technology for people with diabetes
• Enhanced clinical confidence, with products selected through robust, evidence-based processes
• System-wide efficiencies, through reduced variation, streamlined procurement, and better patient outcomes
• Alignment with national priorities, including digital transformation, health equity, and sustainability

Conclusion

Clinical engagement is not a procedural step—it is a strategic enabler. When led by individuals who understand both the clinical and commercial landscape, it becomes a powerful tool for delivering transformation at scale.

At Eladdis, we support organisations to embed clinical engagement into strategic change, procurement, and transformation programmes. If you're looking to deliver smarter, safer innovation—get in touch.